|
Celleration™, Inc. is
a Minnesota based medical device company that has developed a
therapeutic modality (the MIST Therapy System) to treat chronic wounds, such
as diabetic ulcers, pressure ulcers, and vascular ulcers. The patented MIST
technology delivers ultrasound, conveyed through an energized mist of
sterile saline, to the wound bed without direct contact. The therapeutic
effects provided by MIST Therapy include wound cleansing, control of
bacteria colonization, increased blood flow and stimulation of cells to
regenerate tissue growth, all of which contributed to an accelerated wound
healing process. Multi-patient research studies conducted at several sites,
including The Mayo Clinic, provide strong support for the technology’s
ability to speed wound healing. During much of 2003 through today, the
Company has been conducting a multi-center randomized clinical study
involving diabetic foot ulcer patients. Preliminary results from this study
have exceeded original expectations.
www.celleration.com
Birch Point Medical is
a privately held corporation that designs, develops and markets innovative
drug delivery platforms that improve the safety, compliance, effectiveness
and ease of administration of medications, which are delivered into the
body. The Company has developed a proprietary Wearable Electronic
Disposable Drug delivery technology (WEDD™) Platform. WEDD is an innovative
electronic transdermal (iontophoretic) drug delivery system that is totally
self-contained, single-use, portable and disposable.
www.birchpoint.net
HEI
is a full service developer and manufacturer of high performance components,
medical software, medical devices, and non-medical products. HEI produces
microcircuits and subsystems for hearing and medical applications,
communications, and high-speed data processing.
HEI develops software for medical devices, PDA-bases medical applications,
device connectivity, and healthcare information technology applications.
Products include Class I, II and III medical devices, biotechnology, drug
discovery, and in vitro diagnostics systems, and RFID identification
technologies for both healthcare and industry. The company is ISO
certified and FDA registered.
www.heii.com
Biorefining was
incorporated in January of 2000 with the vision to develop, commercialize
and license proprietary technologies capable of economically converting
plant material into value-added products, used primarily for pharmaceutical,
nutraceutical, and functional food applications, in addition to food and
feed grade products. Obtaining their first patent in April of 2002,
Biorefining has continued to expand their proprietary technology portfolio,
which currently holds seven additional patents pending. Biorefining's
technologies maximize the number and value of co-products contained in a
single raw material, fractioning the biomass in several subsequent levels of
processing. To date, Biorefining, Inc. currently maintains three
technologies ready for commercialization: the
Biomilling Process, the
Bio-Extraction Process, and the
Bio-Conversion Process.
Biorefining, Inc. intends to concentrate on the licensing of
their processes to ethanol facilities and other agricultural processors,
providing processing improvements that result in operational efficiencies
and enhanced profitability to the licensees. The Company's first commercial
application of their technology involves their patented Bio-Extraction
Process. This process will be utilized in a $22 million joint-ventured
production facility between Biorefining, Inc. and Ace-Technologies, LLC,
expected to begin production of specialty sugars in early 2005. Ace-Biorefining,
LLC, the world's first "biorefinery", will be located next to the Ace
Ethanol production plant in Stanley, WI. Groundbreaking for the biorefinery
took place on October 24th, 2003. Biorefining, Inc. also intends on
licensing their first level of processing, the Biomilling Process, to
ethanol facilities.
www.biorefining.com
|
...
by Matt Noah
